Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
XDQ.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.4.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.7.6NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XDK.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.64 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.46.4 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.107 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.81 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-22750.3US
AY.117 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.118 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.27 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.617.2 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.67 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.110 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.39.1 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.1.1.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.1.1.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
BA.1.1.14NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.1.20NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.43.4 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
AY.57 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.1.17NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.1.1.8NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.1.1.10NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.1.9NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.7.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
KV.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.16.15NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.39NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JD.1.1.6NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HK.3.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.9NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.7NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HK.3.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26650.4US
JN.1.6NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JG.3.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.22NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.15NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HV.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.58NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.19NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.24NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
KP.4.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
LB.1.7.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.42.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
LA.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used